Compugen (NASDAQ:CGEN) Stock Price Passes Above Two Hundred Day Moving Average – Should You Sell?

Shares of Compugen Ltd. (NASDAQ:CGEN) crossed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $1.74 and traded as high as $2.12. Compugen shares last traded at $2.07, with a volume of 137,147 shares.

Analysts Set New Price Targets

A number of research firms have commented on CGEN. Weiss Ratings reissued a “sell (d-)” rating on shares of Compugen in a report on Wednesday, January 21st. Wall Street Zen raised shares of Compugen from a “hold” rating to a “buy” rating in a research note on Saturday, March 7th. Truist Financial upgraded shares of Compugen to a “strong-buy” rating in a research note on Wednesday. Finally, HC Wainwright initiated coverage on shares of Compugen in a report on Wednesday, January 7th. They set a “buy” rating and a $4.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Compugen presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.00.

Compugen Stock Performance

The stock has a market capitalization of $194.77 million, a PE ratio of 5.57 and a beta of 2.90. The firm has a 50 day moving average of $1.97 and a two-hundred day moving average of $1.74.

Compugen (NASDAQ:CGEN) last posted its earnings results on Monday, March 2nd. The biotechnology company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.05 by $0.55. The company had revenue of $67.33 million for the quarter, compared to the consensus estimate of $14.30 million. Compugen had a return on equity of 55.68% and a net margin of 48.57%. Equities research analysts forecast that Compugen Ltd. will post -0.03 EPS for the current year.

Institutional Investors Weigh In On Compugen

Several institutional investors and hedge funds have recently made changes to their positions in CGEN. Osaic Holdings Inc. increased its holdings in Compugen by 346.0% during the 2nd quarter. Osaic Holdings Inc. now owns 43,885 shares of the biotechnology company’s stock valued at $78,000 after acquiring an additional 34,045 shares in the last quarter. Franklin Resources Inc. purchased a new stake in shares of Compugen in the second quarter valued at about $56,000. Jane Street Group LLC lifted its holdings in shares of Compugen by 1,077.0% in the second quarter. Jane Street Group LLC now owns 393,191 shares of the biotechnology company’s stock valued at $700,000 after purchasing an additional 359,785 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Compugen by 3.7% in the fourth quarter. Renaissance Technologies LLC now owns 1,456,900 shares of the biotechnology company’s stock valued at $2,229,000 after purchasing an additional 51,565 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Compugen by 3.9% during the 4th quarter. State Street Corp now owns 393,802 shares of the biotechnology company’s stock worth $603,000 after purchasing an additional 14,701 shares in the last quarter. 12.22% of the stock is currently owned by hedge funds and other institutional investors.

About Compugen

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.